Introduction#
Sandoz Group AG has announced impressive financial results for the first quarter of 2026, showcasing notable growth in its biosimilar segment. The company’s total net sales reached $2.8 billion, reflecting an 11% increase compared to the previous year.
Company Performance#
The strong performance was largely driven by the biosimilar segment, which saw sales rise to $0.9 billion, making up 31% of total sales. This growth was fueled by increased demand and the successful launch of new medicines. However, the generic segment faced challenges, experiencing a 3% decline due to unfavorable sales timing and adjustments in its product lineup.
Financial Highlights#
- Revenue: $2.8 billion, up 11% year-over-year
- Biosimilar sales: $0.9 billion, representing 31% of total sales
- Volume growth: Contributed 7% to sales
- Foreign exchange impact: Added 8% to revenue
- Price erosion: Negatively affected growth by 4%
Outlook & Guidance#
Looking ahead, Sandoz projects earnings per share (EPS) of $4.04 for FY2026 and $4.65 for FY2027. Revenue forecasts are set at $12.06 billion for FY2026 and $12.61 billion for FY2027. The company expects continued growth in biosimilar sales, supported by ongoing product launches and market expansion.
Executive Commentary#
CEO Richard Saynor emphasized the importance of the biosimilar segment, stating, "Our robust growth in the biosimilar segment underscores our strategic focus and execution capabilities." He noted that the successful launch of new products has been a key driver of sales growth.
Risks and Challenges#
Despite the positive outlook, Sandoz faces risks, particularly from price erosion in the generic segment, which could continue to impact overall performance.